Oncoclinicas Do Brasil Servicos Medicos SA (BSP:ONCO3)

Q3 2024 Oncoclinicas do Brasil Servicos Medicos SA Earnings Call Transcript

Nov 13, 2024 / 02:00 PM GMT

Release Date Price: R$4.32 (+0.90%)

Transcript

Key Points

Positve

Oncoclinicas Do Brasil Servicos Medicos SA (BSP:ONCO3) reported more than 30 million in free cash generation in the third quarter, marking a significant turnaround from previous quarters.
The company achieved a 12.9% growth in gross revenue year-on-year, indicating strong market performance.
There was a notable improvement in receivables management, with provisions for nonpayment reaching the lowest level in two years.
The company has stabilized its leverage at 2.7 times net debt to adjusted EBITDA, showing financial discipline.
Operational cash generation improved significantly, contributing to a positive free cash flow of 20.7 million in the quarter.

Negative

The growth rate slowed down intentionally to prioritize cash generation, which may impact future revenue growth.
Gross margin was pressured due to a mix of treatments and the introduction of new medications with lower initial discounts.
Operating expenses increased due to restructuring costs, impacting the overall financial performance.
The company experienced lower operating leverage due to a temporary reduction in procedures for certain payers.
There is uncertainty regarding the sustainability of the low provision for nonpayment levels, which may not continue in future quarters.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ONCO3.SA - Oncoclinicas do Brasil Servicos Medicos SA
Q3 2024 Oncoclinicas do Brasil Servicos Medicos SA Earnings Call
Nov 13, 2024 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. Welcome to the audio conference of Uncle Kics.

At this moment, all the participants are connected only as listeners and later on, we will initiate the Q&A session for any questions. When instructions will be passed along to you, we should remember that this audio conference is being recorded.

I would like to now pass the word over to Bruno Fead.

Well, Doctor Bruno, please go ahead.

Good morning.

Thank you for participating in our video conference of the results of our third quarter. 2024 earnings call. This quarter marks an important inflection point for Uncle Clinicas from the point of view of the past generation.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.